CLARINET FORTE Baseline Characteristics: Lanreotide Autogel 120 mg (LAN) Every 14 Days in Patients With Progressive Pancreatic or Midgut Neuroendocrine Tumors During a Standard First-Line LAN Regimen
Ruszniewski P, Cwikla J, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Xuan-Mai Truong Thanh , Houchard A, Pavel ME (2020)
Publication Type: Conference contribution
Publication year: 2020
Journal
Publisher: LIPPINCOTT WILLIAMS & WILKINS
City/Town: PHILADELPHIA
Pages Range: 484-485
Conference Proceedings Title: PANCREAS
Authors with CRIS profile
Involved external institutions
University of Warmia and Mazury in Olsztyn
Poland (PL)
Ipsen Pharma
France (FR)
Cliniques universitaires Saint-Luc (CHU St-Luc)
Belgium (BE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Hôpital Edouard Herriot
France (FR)
Queen Elizabeth Hospital
United Kingdom (GB)
University of Paris 4 - Paris-Sorbonne / Université paris IV Paris-Sorbonne
France (FR)
Poland (PL)
Ipsen Pharma
France (FR)
Cliniques universitaires Saint-Luc (CHU St-Luc)
Belgium (BE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Hôpital Edouard Herriot
France (FR)
Queen Elizabeth Hospital
United Kingdom (GB)
University of Paris 4 - Paris-Sorbonne / Université paris IV Paris-Sorbonne
France (FR)
How to cite
APA:
Ruszniewski, P., Cwikla, J., Lombard-Bohas, C., Borbath, I., Shah, T., Pape, U.-F.,... Pavel, M.E. (2020). CLARINET FORTE Baseline Characteristics: Lanreotide Autogel 120 mg (LAN) Every 14 Days in Patients With Progressive Pancreatic or Midgut Neuroendocrine Tumors During a Standard First-Line LAN Regimen. In PANCREAS (pp. 484-485). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
MLA:
Ruszniewski, Philippe, et al. "CLARINET FORTE Baseline Characteristics: Lanreotide Autogel 120 mg (LAN) Every 14 Days in Patients With Progressive Pancreatic or Midgut Neuroendocrine Tumors During a Standard First-Line LAN Regimen." Proceedings of the PANCREAS PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS, 2020. 484-485.
BibTeX: Download